HUE052090T2 - A SYK inhibitorok polimorfja - Google Patents
A SYK inhibitorok polimorfjaInfo
- Publication number
- HUE052090T2 HUE052090T2 HUE14750289A HUE14750289A HUE052090T2 HU E052090 T2 HUE052090 T2 HU E052090T2 HU E14750289 A HUE14750289 A HU E14750289A HU E14750289 A HUE14750289 A HU E14750289A HU E052090 T2 HUE052090 T2 HU E052090T2
- Authority
- HU
- Hungary
- Prior art keywords
- polymorph
- syk inhibitors
- syk
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361860197P | 2013-07-30 | 2013-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE052090T2 true HUE052090T2 (hu) | 2021-04-28 |
Family
ID=51301367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE14750289A HUE052090T2 (hu) | 2013-07-30 | 2014-07-29 | A SYK inhibitorok polimorfja |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US20160168155A1 (hu) |
| EP (1) | EP3027618B1 (hu) |
| JP (1) | JP6230709B2 (hu) |
| KR (1) | KR101810798B1 (hu) |
| CN (1) | CN105452252A (hu) |
| AP (1) | AP2016009008A0 (hu) |
| AR (1) | AR097158A1 (hu) |
| AU (2) | AU2014296308C1 (hu) |
| CA (1) | CA2919661C (hu) |
| CL (1) | CL2016000238A1 (hu) |
| CR (1) | CR20160098A (hu) |
| DK (1) | DK3027618T3 (hu) |
| EA (2) | EA201791873A1 (hu) |
| ES (1) | ES2822285T3 (hu) |
| HK (1) | HK1222390A1 (hu) |
| HR (1) | HRP20201582T1 (hu) |
| HU (1) | HUE052090T2 (hu) |
| IL (1) | IL243579A0 (hu) |
| MD (1) | MD4659B1 (hu) |
| MX (1) | MX2016001304A (hu) |
| MY (1) | MY176803A (hu) |
| NZ (1) | NZ715776A (hu) |
| PE (1) | PE20160862A1 (hu) |
| PH (1) | PH12016500169A1 (hu) |
| PL (1) | PL3027618T3 (hu) |
| PT (1) | PT3027618T (hu) |
| SG (1) | SG11201600385TA (hu) |
| SI (1) | SI3027618T1 (hu) |
| SV (1) | SV2016005149A (hu) |
| TW (1) | TW201602108A (hu) |
| UY (1) | UY35683A (hu) |
| WO (1) | WO2015017460A1 (hu) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104059073B (zh) | 2008-12-08 | 2017-04-12 | 吉利德康涅狄格公司 | 咪唑并哌嗪syk抑制剂 |
| KR101717809B1 (ko) | 2010-03-11 | 2017-03-17 | 질레드 코네티컷 인코포레이티드 | 이미다조피리딘 ｓｙｋ 억제제 |
| ES2822285T3 (es) | 2013-07-30 | 2021-04-30 | Kronos Bio Inc | Polimorfo de inhibidores de SYK |
| SI3027171T1 (sl) * | 2013-07-30 | 2020-08-31 | Gilead Connecticut, Inc. | Formulacija inhibitorjev SYK |
| KR20180002888A (ko) | 2013-12-04 | 2018-01-08 | 길리애드 사이언시즈, 인코포레이티드 | 암을 치료하는 방법 |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
| UY35898A (es) | 2013-12-23 | 2015-07-31 | Gilead Sciences Inc | ?compuestos inhibidores de syk y composiciones que los comprenden?. |
| BR112016028641A2 (pt) * | 2014-07-14 | 2017-08-22 | Gilead Sciences Inc | ?método para tratar câncer? |
| TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| KR20170137200A (ko) | 2015-04-21 | 2017-12-12 | 길리애드 사이언시즈, 인코포레이티드 | Syk 억제제를 사용한 만성 이식편 대 숙주 질환의 치료 |
| WO2017106564A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders |
| CN109071547A (zh) * | 2016-02-26 | 2018-12-21 | 苏州晶云药物科技股份有限公司 | (6-(1H-吲唑-6-基)-N-[4-(4-吗啉基)苯基]咪唑并[1,2-a]吡嗪-8-胺)甲磺酸盐的新晶型 |
| TW201822764A (zh) | 2016-09-14 | 2018-07-01 | 美商基利科學股份有限公司 | Syk抑制劑 |
| US10111882B2 (en) | 2016-09-14 | 2018-10-30 | Gilead Sciences, Inc. | SYK inhibitors |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| WO2018195471A1 (en) | 2017-04-21 | 2018-10-25 | Gilead Sciences, Inc. | Syk inhibitors in combination with hypomethylating agents |
| CA3073871A1 (en) * | 2017-08-25 | 2019-02-28 | Gilead Sciences, Inc. | Polymorphs of syk inhibitors |
| TWI796596B (zh) | 2018-02-13 | 2023-03-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| JP7242702B2 (ja) | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| CA3099152C (en) | 2018-05-14 | 2023-10-24 | Gilead Sciences, Inc. | Mcl-1 inhibitors |
| EP4234030A3 (en) | 2018-07-13 | 2023-10-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN112955435A (zh) | 2018-10-24 | 2021-06-11 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| CN113950479A (zh) | 2019-02-22 | 2022-01-18 | 克洛诺斯生物股份有限公司 | 作为syk抑制剂的缩合吡嗪的固体形式 |
| CN113402506B (zh) * | 2021-06-17 | 2023-06-16 | 四川大学 | 中间体和制备方法及其在合成长春布宁上的应用 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2607813B1 (fr) | 1986-12-05 | 1989-03-31 | Montpellier I Universite | Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique |
| US5137876A (en) | 1990-10-12 | 1992-08-11 | Merck & Co., Inc. | Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same |
| DE4327027A1 (de) | 1993-02-15 | 1994-08-18 | Bayer Ag | Imidazoazine |
| DE4337611A1 (de) | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| DE4337609A1 (de) | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| FR2711993B1 (fr) | 1993-11-05 | 1995-12-01 | Rhone Poulenc Rorer Sa | Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation. |
| BR9507200A (pt) | 1994-03-25 | 1997-09-16 | Isotechnika Inc | Melhora da eficácia de drogas por deuteração |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| FR2723373B1 (fr) | 1994-08-02 | 1996-09-13 | Rhone Poulenc Rorer Sa | Forme purifiee de streptogramines, sa preparation et les compositions pharmaceutiques qui la contiennent |
| WO1996034866A1 (en) | 1995-05-01 | 1996-11-07 | Fujisawa Pharmaceutical Co., Ltd. | Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivatives and their use as bone resorption inhibitors |
| US5593997A (en) | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
| SE9704404D0 (sv) | 1997-11-28 | 1997-11-28 | Astra Ab | New compounds |
| DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
| JP2001302667A (ja) | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| GB0018473D0 (en) | 2000-07-27 | 2000-09-13 | Merck Sharp & Dohme | Therapeutic agents |
| DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
| CA2436487A1 (en) | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd. | Methods of inhibiting kinases |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| AU2003219690A1 (en) | 2002-02-19 | 2003-09-09 | Pharmacia And Upjohn Company | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
| IL164703A0 (en) | 2002-04-19 | 2005-12-18 | Cellular Genomics Inc | ImidazoÄ1,2-AÜpyrazin-8-ylamines method of making and method of use thereof |
| KR101060971B1 (ko) | 2002-05-14 | 2011-09-01 | 제노바 리미티드 | 안트라닐산 유도체 수화물의 제조 방법 |
| WO2004022562A1 (en) | 2002-09-09 | 2004-03-18 | Cellular Genomics, Inc. | 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF |
| CN100549011C (zh) | 2002-09-19 | 2009-10-14 | 先灵公司 | 用作细胞周期蛋白依赖性激酶抑制剂的新颖咪唑并吡啶 |
| KR20060010709A (ko) | 2002-09-23 | 2006-02-02 | 쉐링 코포레이션 | 사이클린 의존성 키나제 억제제로서의 신규한 이미다조피라진 |
| EP1543008B1 (en) | 2002-09-23 | 2007-11-07 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
| US7160885B2 (en) | 2003-02-10 | 2007-01-09 | Cgi Pharmaceuticals, Inc. | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity |
| US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| US7186832B2 (en) | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
| US20060183746A1 (en) | 2003-06-04 | 2006-08-17 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| WO2005005429A1 (en) | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds |
| WO2005019220A2 (en) | 2003-08-11 | 2005-03-03 | Cellular Genomics Inc. | Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity |
| US20050288295A1 (en) | 2003-11-11 | 2005-12-29 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| WO2005085252A1 (en) | 2004-03-04 | 2005-09-15 | Biofocus Discovery Limited | Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases |
| US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| WO2006053121A2 (en) | 2004-11-10 | 2006-05-18 | Cgi Pharmaceuticals, Inc. | Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
| NZ561609A (en) | 2005-05-12 | 2010-03-26 | Abbott Lab | 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters |
| RU2008122967A (ru) | 2005-11-10 | 2009-12-20 | Шеринг Корпорейшн (US) | Имидазопиразины в качестве ингибиторов протеинкиназ |
| WO2008025821A1 (en) | 2006-08-30 | 2008-03-06 | Cellzome Limited | Triazole derivatives as kinase inhibitors |
| AR063706A1 (es) | 2006-09-11 | 2009-02-11 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
| CL2008002793A1 (es) | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
| WO2009070639A1 (en) | 2007-11-28 | 2009-06-04 | Irx Therapeutics, Inc. | Method of increasing immunological effect |
| CN101952283B (zh) | 2007-12-14 | 2013-04-17 | 霍夫曼-拉罗奇有限公司 | 咪唑并[1，2-a]吡啶和咪唑并[1，2-b]哒嗪衍生物 |
| WO2009102468A1 (en) | 2008-02-13 | 2009-08-20 | Cgi Pharmaceuticals, Inc. | 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof |
| CA2719115A1 (en) | 2008-03-07 | 2009-09-11 | Pfizer Inc. | Methods, dosage forms, and kits for administering ziprasidone without food |
| PE20100851A1 (es) | 2008-06-24 | 2011-01-31 | Hoffmann La Roche | PIRIDIN-2-ONAS Y PIRIDAZIN-3-ONAS SUSTITUIDAS COMO INHIBIDORES DE Btk |
| EP2300459B1 (en) | 2008-07-02 | 2013-05-29 | F. Hoffmann-La Roche AG | Novel phenylpyrazinones as kinase inhibitors |
| WO2010006947A1 (en) | 2008-07-15 | 2010-01-21 | F. Hoffmann-La Roche Ag | Novel phenyl-imidazopyridines and pyridazines |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| CN104059073B (zh) | 2008-12-08 | 2017-04-12 | 吉利德康涅狄格公司 | 咪唑并哌嗪syk抑制剂 |
| US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| CN104744476B (zh) | 2008-12-08 | 2017-04-12 | 吉利德康涅狄格公司 | 咪唑并吡嗪syk抑制剂 |
| US8362013B2 (en) | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2011074961A1 (en) | 2009-12-18 | 2011-06-23 | Frieslandcampina Nederland Holding B.V. | Co-processed tablet excipient composition its preparation and use |
| KR101717809B1 (ko) | 2010-03-11 | 2017-03-17 | 질레드 코네티컷 인코포레이티드 | 이미다조피리딘 ｓｙｋ 억제제 |
| AU2011332043C1 (en) | 2010-11-23 | 2016-11-10 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
| EP2703400A4 (en) * | 2011-04-27 | 2014-10-08 | Daiichi Sankyo Co Ltd | PHENYLPYRROLDERIVAT CRYSTAL |
| US20130338142A1 (en) | 2012-06-14 | 2013-12-19 | Gilead Connecticut, Inc. | Imidazopyrazine syk inhibitors |
| JP2015529195A (ja) | 2012-08-14 | 2015-10-05 | ギリアード カリストガ エルエルシー | 癌を処置するための組合せ治療 |
| US20140148430A1 (en) | 2012-11-26 | 2014-05-29 | Gilead Connecticut, Inc. | Imidazopyridines syk inhibitors |
| SI3027171T1 (sl) | 2013-07-30 | 2020-08-31 | Gilead Connecticut, Inc. | Formulacija inhibitorjev SYK |
| ES2822285T3 (es) | 2013-07-30 | 2021-04-30 | Kronos Bio Inc | Polimorfo de inhibidores de SYK |
| AU2014296184B2 (en) | 2013-07-31 | 2017-04-27 | Gilead Sciences, Inc. | Syk inhibitors |
| KR20180002888A (ko) | 2013-12-04 | 2018-01-08 | 길리애드 사이언시즈, 인코포레이티드 | 암을 치료하는 방법 |
| UY35898A (es) | 2013-12-23 | 2015-07-31 | Gilead Sciences Inc | ?compuestos inhibidores de syk y composiciones que los comprenden?. |
| TR201906413T4 (tr) | 2013-12-23 | 2019-05-21 | Gilead Sciences Inc | Bir makrosiklik hcv ns3 inhibe edici tripeptidin sentezi. |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
| BR112016028641A2 (pt) | 2014-07-14 | 2017-08-22 | Gilead Sciences Inc | ?método para tratar câncer? |
| TW201617074A (zh) | 2014-07-14 | 2016-05-16 | 吉李德科學股份有限公司 | Ｓｙｋ（脾酪胺酸激酶）抑制劑 |
| TW201639573A (zh) * | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| KR20170137200A (ko) | 2015-04-21 | 2017-12-12 | 길리애드 사이언시즈, 인코포레이티드 | Syk 억제제를 사용한 만성 이식편 대 숙주 질환의 치료 |
-
2014
- 2014-07-29 ES ES14750289T patent/ES2822285T3/es active Active
- 2014-07-29 EA EA201791873A patent/EA201791873A1/ru unknown
- 2014-07-29 PE PE2016000197A patent/PE20160862A1/es unknown
- 2014-07-29 US US14/907,767 patent/US20160168155A1/en not_active Abandoned
- 2014-07-29 DK DK14750289.2T patent/DK3027618T3/da active
- 2014-07-29 MY MYPI2016700285A patent/MY176803A/en unknown
- 2014-07-29 AP AP2016009008A patent/AP2016009008A0/xx unknown
- 2014-07-29 NZ NZ715776A patent/NZ715776A/en not_active IP Right Cessation
- 2014-07-29 PL PL14750289T patent/PL3027618T3/pl unknown
- 2014-07-29 JP JP2016531837A patent/JP6230709B2/ja active Active
- 2014-07-29 CN CN201480043503.5A patent/CN105452252A/zh active Pending
- 2014-07-29 SG SG11201600385TA patent/SG11201600385TA/en unknown
- 2014-07-29 KR KR1020167005206A patent/KR101810798B1/ko active IP Right Grant
- 2014-07-29 EA EA201690172A patent/EA029281B1/ru active IP Right Revival
- 2014-07-29 PT PT147502892T patent/PT3027618T/pt unknown
- 2014-07-29 EP EP14750289.2A patent/EP3027618B1/en active Active
- 2014-07-29 MX MX2016001304A patent/MX2016001304A/es unknown
- 2014-07-29 TW TW103125870A patent/TW201602108A/zh unknown
- 2014-07-29 HU HUE14750289A patent/HUE052090T2/hu unknown
- 2014-07-29 US US14/446,011 patent/US9657023B2/en active Active
- 2014-07-29 MD MD20160017A patent/MD4659B1/ro not_active IP Right Cessation
- 2014-07-29 CA CA2919661A patent/CA2919661C/en active Active
- 2014-07-29 WO PCT/US2014/048733 patent/WO2015017460A1/en active Application Filing
- 2014-07-29 SI SI201431675T patent/SI3027618T1/sl unknown
- 2014-07-29 AU AU2014296308A patent/AU2014296308C1/en not_active Ceased
- 2014-07-30 AR ARP140102857A patent/AR097158A1/es unknown
- 2014-07-30 UY UY35683A patent/UY35683A/es not_active Application Discontinuation
-
2016
- 2016-01-12 IL IL243579A patent/IL243579A0/en unknown
- 2016-01-25 PH PH12016500169A patent/PH12016500169A1/en unknown
- 2016-01-29 SV SV2016005149A patent/SV2016005149A/es unknown
- 2016-01-29 CL CL2016000238A patent/CL2016000238A1/es unknown
- 2016-02-29 CR CR20160098A patent/CR20160098A/es unknown
- 2016-09-05 HK HK16110532.6A patent/HK1222390A1/zh unknown
-
2017
- 2017-04-11 US US15/484,844 patent/US20170217967A1/en not_active Abandoned
- 2017-09-08 AU AU2017225136A patent/AU2017225136A1/en not_active Abandoned
- 2017-10-19 US US15/788,583 patent/US10266539B2/en active Active
-
2020
- 2020-10-05 HR HRP20201582TT patent/HRP20201582T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1222390A1 (zh) | 抑制劑的多晶型 | |
| HK1256999A1 (zh) | Syk抑制劑 | |
| HK1222329A1 (zh) | 抑制劑的製劑 | |
| IL243578A0 (en) | syk inhibitors | |
| GB201410735D0 (en) | Method of inhibiting DYRK1B | |
| HK1211024A1 (en) | Inhibitors of syk syk | |
| HK1222339A1 (zh) | 金屬-β-內酰胺酶的抑制劑 | |
| IL240763B (en) | The halopyrazoles as thrombin inhibitors | |
| EP3003320A4 (en) | NEW POLYMORPHE OF REGADENOSON | |
| ZA201507100B (en) | Synthesis of bace1 inhibitors | |
| HK1221159A1 (zh) | 轉移抑制劑 | |
| EP2959896A4 (en) | INHIBITOR OF PHOSPHORYLATION OF PROTEIN T |